Is radioiodine ablation with 30 mCi 131I necessary in low-risk thyroid cancer patients? Results from a long-term follow-up prospective study.
Abstract In patients with low-risk differentiated thyroid cancer (DTC), remnant ablation with radioiodine (RA) after total thyroidectomy (TT) is controversial. No benefits have been demonstrated in terms of mortality or disease-free survival. Recent evidence found that RA did not improve mid-term outcomes. Purpose: to evaluate initial response to treatment and long-term follow-up status in low-risk DTC patients after TT vs. TT+RA. Methods: prospective multicenter non-randomized study; 174 low-risk DTC that underwent TT were recruited and were divided in two groups according to RA (87 ablated and 87 non-ablated). Response to treatment was evaluated between 6-18 months after thyroidectomy and at the end of follow-up with thyroglobulin, anti-thyroglobulin antibodies levels and neck ultrasonography. Results: baseline characteristics of both groups were similar. Ablated patients: median age 45.5 years, 84% females, 95.4% papillary thyroid carcinoma (PTC), mean tumor size 16mm; non-ablated: median age 45 years, 88.5% females, 96.6% PTC, mean tumor size 14 mm. Response to initial treatment was similar between both groups, with less than 2% of structural incomplete response. Final status was evaluated in 139 cases after a median follow-up of 60 months. Among ablated patients, 82.8% had no evidence of disease (NED), 12% had an indeterminate response (IR) and 5% a biochemical incomplete response (BIR). Non-ablated patients had NED in 90%, IR in 8.7% and BIR in 1.2%. No statistical difference was found between groups (p=0.29). No patient had evidence of structural disease at the end of follow-up. Conclusions:our findings support the recommendation against routine RA in low-risk DTC patients..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
ResearchSquare.com - (2023) vom: 16. Okt. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ilera, Veronica [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| doi: |
10.21203/rs.3.rs-2359357/v1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XRA038229358 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XRA038229358 | ||
| 003 | DE-627 | ||
| 005 | 20231205145804.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 221221s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21203/rs.3.rs-2359357/v1 |2 doi | |
| 035 | |a (DE-627)XRA038229358 | ||
| 035 | |a (ResearchSquare)10.21203/rs.3.rs-2359357/v1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ilera, Veronica |e verfasserin |0 (orcid)0000-0003-1724-9390 |4 aut | |
| 245 | 1 | 0 | |a Is radioiodine ablation with 30 mCi 131I necessary in low-risk thyroid cancer patients? Results from a long-term follow-up prospective study. |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract In patients with low-risk differentiated thyroid cancer (DTC), remnant ablation with radioiodine (RA) after total thyroidectomy (TT) is controversial. No benefits have been demonstrated in terms of mortality or disease-free survival. Recent evidence found that RA did not improve mid-term outcomes. Purpose: to evaluate initial response to treatment and long-term follow-up status in low-risk DTC patients after TT vs. TT+RA. Methods: prospective multicenter non-randomized study; 174 low-risk DTC that underwent TT were recruited and were divided in two groups according to RA (87 ablated and 87 non-ablated). Response to treatment was evaluated between 6-18 months after thyroidectomy and at the end of follow-up with thyroglobulin, anti-thyroglobulin antibodies levels and neck ultrasonography. Results: baseline characteristics of both groups were similar. Ablated patients: median age 45.5 years, 84% females, 95.4% papillary thyroid carcinoma (PTC), mean tumor size 16mm; non-ablated: median age 45 years, 88.5% females, 96.6% PTC, mean tumor size 14 mm. Response to initial treatment was similar between both groups, with less than 2% of structural incomplete response. Final status was evaluated in 139 cases after a median follow-up of 60 months. Among ablated patients, 82.8% had no evidence of disease (NED), 12% had an indeterminate response (IR) and 5% a biochemical incomplete response (BIR). Non-ablated patients had NED in 90%, IR in 8.7% and BIR in 1.2%. No statistical difference was found between groups (p=0.29). No patient had evidence of structural disease at the end of follow-up. Conclusions:our findings support the recommendation against routine RA in low-risk DTC patients. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Califano, Inés |4 aut | |
| 700 | 1 | |a Cavallo, Andrea |4 aut | |
| 700 | 1 | |a Faure, Eduardo |4 aut | |
| 700 | 1 | |a Vázquez, Adriana |4 aut | |
| 700 | 1 | |a Pitoia, Fabián |0 (orcid)0000-0002-2742-7085 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ResearchSquare.com |g (2023) vom: 16. Okt. |
| 773 | 1 | 8 | |g year:2023 |g day:16 |g month:10 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s12020-023-03306-w |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21203/rs.3.rs-2359357/v1 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XRA | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 16 |c 10 | ||